Impact of Chemotherapeutic Agents on PD-L1, CTLA-4, and VISTA Gene Expression in Cervical Cancer Cell Lines: An In Vitro Study

Hadi Nasiri, Mahya Ahmadpour Youshanlui, Zahra Valedkarimi, Javad Ahmadian Heris, Ahad Mokhtarzadeh, Dariush Shanehbandi, Hanieh Ahmadi, Ali Jafarizadeh and Behzad Baradaran

Indian J Gynecol Oncolog, 2024, 22
DOI: 10.1007/s40944-024-00828-7

Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities

Jessica M. Konen, Haoyi Wu and Don L. Gibbons

Trends in Pharmacological Sciences, 2024, 45, 520
DOI: 10.1016/j.tips.2024.04.006

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma

Masaud Shah, Muhammad Hussain and Hyun Goo Woo

Genom. Inform., 2025, 23
DOI: 10.1186/s44342-024-00033-0

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade

Przemysław Bielski, Jan Barczyński, Michał Mikitiuk, Maja Myrcha, Kamil Rykała, Louis Boon, Wiktoria Gąsior, Aleksandra Hec-Gałązka, Tad A. Holak and Tomasz Sitar

Front. Immunol., 2025, 16
DOI: 10.3389/fimmu.2025.1486799

Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy

Zibing Qian, Wanyuan Xiong, Xiaorong Mao and Junfeng Li

Biomolecules, 2024, 14, 700
DOI: 10.3390/biom14060700

VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis

Xiaoshuang Niu, Beibei Li, Feiyu Luo, Wanqiong Li, Xiuman Zhou and Wenshan Zhao

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025, 1880, 189351
DOI: 10.1016/j.bbcan.2025.189351

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

Thomas Thisted, F. Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H. Martin, Yoshiko Takeuchi, Kader Thiam, Robert D. Schreiber and Edward H. van der Horst

Nat Commun, 2024, 15
DOI: 10.1038/s41467-024-47256-x

Myocarditis Induced by Immune Checkpoint Inhibitors: An Exploratory Review

Esteban Zavaleta-Monestel, Jonathan García-Montero, Adriana Anchía-Alfaro, Carolina Rojas-Chinchilla, Ricardo Quesada-Villaseñor, Sebastián Arguedas-Chacón, Monserrat Barrantes-López, Paula Molina-Sojo, Andrea Zovi and Carlos Zúñiga-Orlich

Cureus, 2024
DOI: 10.7759/cureus.67314

Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy

Sufian Zaheer and Niti Sureka

Korean J Clin Oncol, 2025, 21, 47
DOI: 10.14216/kjco.24322

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature

Ruchi Yadav, Narek Hakobyan and Jen-Chin Wang

IJMS, 2023, 24, 12502
DOI: 10.3390/ijms241512502

Exploring IgSF11 as a potential immune checkpoint and immunotherapeutic target in breast cancer

Ibtissam Rezouki, Basma Zohair, Hamza Benthami, Mehdi Karkouri, Ibtissam Razzouki and Abdallah Badou

Cancer Immunol Immunother, 2025, 74
DOI: 10.1007/s00262-025-04095-z

Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity

Taylor J Moon, Hieu Minh Ta, Anubhuti Bhalotia, Kai E Paulsen, Diarmuid W Hutchinson, Gabrielle M Arkema, Andrew S Choi, Michiko G Haynie, Laolu Ogunnaike, Margee Dever, Li Lily Wang and Efstathios Karathanasis

J Immunother Cancer, 2024, 12, e008977
DOI: 10.1136/jitc-2024-008977

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Moksada Regmi, Yingjie Wang, Weihai Liu, Yuwei Dai, Shikun Liu, Ke Ma, Guozhong Lin, Jun Yang, Hongyi Liu, Jian Wu and Chenlong Yang

J Exp Clin Cancer Res, 2024, 43
DOI: 10.1186/s13046-024-02973-5

Computational Mapping of Conformational Dynamics and Interaction Hotspots of Human VISTA with pH-Selective Antibodies

Norman Ly, Shubham Devesh Ramgoolam and Aravindhan Ganesan

Biochemistry, 2025, 64, 3634
DOI: 10.1021/acs.biochem.4c00863

Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway

Shuai Zheng, Kuojun Zhang, Xiangyu Zhang, Yibei Xiao, Tianyu Wang and Sheng Jiang

J. Med. Chem., 2022, 65, 11900
DOI: 10.1021/acs.jmedchem.2c00803

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy

Xiaoshuang Niu, Menghan Wu, Guodong Li, Xiuman Zhou, Wenpeng Cao, Wenjie Zhai, Aijun Wu, Xiaowen Zhou, Shengzhe Jin, Guanyu Chen, Yanying Li, Jiangfeng Du, Yahong Wu, Lu Qiu, Wenshan Zhao and Yanfeng Gao

Acta Pharmaceutica Sinica B, 2023, 13, 4511
DOI: 10.1016/j.apsb.2023.08.003

VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy

Najibeh Shekari, Dariush Shanehbandi, Tohid Kazemi, Habib Zarredar, Behzad Baradaran and Seyed Amir Jalali

Cancer Cell Int, 2023, 23
DOI: 10.1186/s12935-023-03116-0

Review of immunotherapy in non-small cell lung cancer: mechanisms, clinical applications, and future prospects

Palwasha Habib

Asia-Pac J Oncol, 2024
DOI: 10.32948/ajo.2024.09.08

Current Advances in Immunotherapy Management of Esophageal Cancer

Sagar Pyreddy, Sarah Kim, William Miyamoto, Zohray Talib, Dev A. GnanaDev and Amir A. Rahnemai-Azar

Cancers, 2025, 17, 851
DOI: 10.3390/cancers17050851

Immune checkpoint blockade for cancer therapy: current progress and perspectives

Hongying Ye, Weijie Liao, Jiongli Pan, Yin Shi and Qingqing Wang

J. Zhejiang Univ. Sci. B, 2025, 26, 203
DOI: 10.1631/jzus.B2300492

Toward the clinical development of synthetic immunity to cancer

Julie M. Garcia, Cassandra E. Burnett and Kole T. Roybal

Immunological Reviews, 2023, 320, 83
DOI: 10.1111/imr.13245

Tissue biomarkers of immune checkpoint inhibitor therapy

Fatemeh Davoudi, Afshin Moradi, Habib Sadeghirad and Arutha Kulasinghe

Immunol Cell Biol, 2024, 102, 179
DOI: 10.1111/imcb.12723